
All.Can Canada Roundtable Report November 14, 2019

Context:

Efforts to establish a Canadian affiliate of All.Can International have recently been underway. To that end, a multi-stakeholder roundtable session was held in Toronto on November 14, 2019 which included review of the *Consolidated Report on Inefficiencies and Waste in Canada* by participants. With that as the basis, participants brainstormed what distinctive contribution All.Can Canada could make to improve the cancer journey for Canadian patients.

This report outlines the consensus achieved at that meeting, and the details of the next steps agreed upon by the participants with the aim of establishing All.Can Canada as a contributor to the Canadian cancer community.

Attendees:

- Kathy Barnard, President, Save Your Skin Foundation
- Elizabeth Lye, Lymphoma Canada
- Eva Villalba, Director General, Coalition Priorité Cancer au Quebec
- Natalie Richardson, Save Your Skin Foundation
- Chantele Burroughs, Save Your Skin Foundation
- Antonella Scali, Executive Director, Canadian Psoriasis Network
- Martine Elias, Executive Director, Myeloma Canada
- Josee Pelletier, Bristol-Myers Squibb
- Louise Binder, Health Policy Consultant, Save Your Skin Foundation
- Wendy Morton, Associate Director, National Policy Planning, Merck Canada Inc.
- Suzanne Wait, Managing Director, The Health Policy Partnership
- Shivani Kapoor, Janssen Canada
- Alex Chambers, Novartis Pharmaceuticals Canada (formerly of CADTH)
- Dr. Tony Fields, retired medical oncologist and former medical head of Cancer Care Alberta
- Anita Simon, Health Policy Consultant

Consultants:

- Leah Stephenson, Leah M. Stephenson Consulting, meeting facilitator
- Gerry Jeffcott, 3Sixty Public Affairs, meeting reporter

Meeting Objectives:

- To identify priority areas of action for All.Can Canada
- To strategize and develop actionable recommendations and next steps together

Consensus Statement:

All.Can Canada will focus on optimizing patient entry into Canadian cancer care systems, ensuring swift, accurate and appropriately delivered diagnosis and that patients experience coordinated, effective support throughout their cancer journey. The preliminary focus will be on ensuring swift, accurate and appropriately delivered diagnosis as the entry point into the cancer care system.

Next Steps:

Advance the identified consensus by forming an interim multi-stakeholder Steering Committee that is responsible for providing strategic guidance and oversight of two objectives to be completed during the next 12-24 months as follows:

1. Oversee the preparation of a rigorous environmental scan to:
 - a. Assess the current state of cancer care systems in Canada to “ensure swift, accurate and appropriately delivered diagnosis as the entry point into the cancer care system”;
 - b. Identify promising, good, and best practices in Canada in cancer care diagnosis that could be adapted, expanded, and scaled up elsewhere, and draw lessons learnt;
 - c. Analyze what works well, enablers, issues, barriers and gaps to be addressed, including benchmarking or comparisons between jurisdictions and/or cancer types where possible;
 - d. Analyze specific areas of inefficiency related to cancer diagnoses that represent opportunities for improvement;
 - e. Summarize findings into an engaging, well referenced policy report, principally targeted at policymakers across Canada but applicable to a range of stakeholders.
2. Convene a second, multi-stakeholder roundtable meeting to assess the results of the environmental scan and determine the objections and action plan to guide the work of All.Can Canada.

Save Your Skin Foundation, All.Can Canada’s Secretariat, is responsible for supporting implementation.



About All.Can

All.Can is an international, multi-stakeholder policy initiative aiming to identify ways we can optimize the use of resources in cancer care by focusing on outcomes that matter most to patients – and create greater efficiency in cancer care. This involves examining what system inefficiencies exist, finding examples of how we can improve efficiency in cancer care and implementing concrete policy actions based on these findings.

All.Can is comprised of leading representatives from patient organizations, policymakers, health care professionals, research and industry. The All.Can Group consists of All.Can International, plus All.Can national initiatives currently established in 14 countries including Canada.

About All.Can Canada

Save Your Skin Foundation (SYSF) is a national, patient-led, not-for-profit group dedicated to leading the fight against non-melanoma skin cancers, melanoma and ocular melanoma. SYSF was established as All.Can Canada's Secretariat to lead the initiative in Canada, bringing the approach and lessons learned by the international group to Canada. To start, SYSF convened a working group to discuss how best to bring All.Can into Canadian health care.

The working group has completed a discovery phase that involved a literature review of nation-wide and province-specific health care reports to identify the top reported areas of waste and inefficiency in cancer care in Canada. These findings were then prioritized through anonymous surveys with cancer care stakeholder groups, including pharmaceutical industry representatives, patient group representatives, health care professionals, provincial policy makers, and health technology assessment bodies. This information was also reviewed in light of responses from over 300 Canadian cancer patients who took part in the All.Can International Patient Survey.

Following this discovery phase, SYSF hosted an inaugural multi-stakeholder roundtable meeting to find consensus on priorities and next steps to move All.Can Canada forward. As a result, an All.Can Canada Interim Steering Committee is being assembled with representation from all stakeholder groups to support, guide and oversee the progress of a multi-year project that was derived from the roundtable.

At the Canadian level, the All.Can Canada initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Merck, Novartis and Janssen.

For more information visit <https://www.all-can.org/national-initiatives/canada/>